Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows
Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation titled, “Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (rib),” at the European Society for Medical Oncology (ESMO) 2019 Congress, held Sept. 27–Oct. 1, in Barcelona, Spain. Kisqali is a targeted therapy marketed by Novartis. It works by interfering with the activity of cyclin-dependent kinases (CDK) 4/6, which are enzymes that regulate cell proliferation and growth, and often are overactive in breast cancer. It is
Subscribe or to access all post and page content.